Download PDF

1. Company Snapshot

1.a. Company Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders.The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer.


The company has a strategic collaboration agreement with Gilead Sciences, Inc.for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc.and changed its name to Nurix Therapeutics, Inc.


in October 2018.The company was incorporated in 2009 and is headquartered in San Francisco, California.

Show Full description

1.b. Last Insights on NRIX

The recent 3-month performance of Nurix Therapeutics, Inc. was driven by several factors. The company reported a Q1 loss, but managed to top revenue estimates. Additionally, Nurix stock gained as Sanofi in-licensed rights to an autoimmune diseases program, and the company granted inducement awards to new employees. Furthermore, Nurix announced FDA clearance of an IND application for a novel IRAK4 degrader, which has potential clinical applications across multiple blockbuster markets in inflammation. The company also received a $15 million license extension fee from Sanofi and is eligible for an additional $465 million in development, regulatory and commercial milestones for this program.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Dec -06

Source: globenewswire.com

Card image cap

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec -01

Source: globenewswire.com

Card image cap

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov -25

Source: globenewswire.com

Card image cap

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

Nov -10

Source: globenewswire.com

Card image cap

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

Nov -07

Source: globenewswire.com

Card image cap

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Nov -03

Source: globenewswire.com

Card image cap

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct -30

Source: globenewswire.com

Card image cap

Sumitomo Mitsui Trust Group Inc. Acquires 635,668 Shares of Nurix Therapeutics, Inc. $NRIX

Oct -30

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.93%)

6. Segments

Small Molecule and Cell Therapies

Expected Growth: 10.93%

Nurix Therapeutics' Small Molecule and Cell Therapies segment growth is driven by increasing adoption of novel cancer treatments, rising demand for targeted therapies, and advancements in gene editing technologies. Additionally, strategic partnerships, expanding pipeline, and growing R&D investments contribute to the 10.93% growth rate.

7. Detailed Products

Deubiquitinase Inhibitors

Nurix Therapeutics' deubiquitinase inhibitors are small molecule compounds that target specific deubiquitinase enzymes, which play a crucial role in protein degradation and cellular regulation.

E3 Ligase Modulators

Nurix's E3 ligase modulators are small molecules that target specific E3 ubiquitin ligases, which are enzymes that regulate protein ubiquitination and degradation.

Protein Degradation Therapies

Nurix's protein degradation therapies utilize targeted protein degradation to eliminate disease-causing proteins, offering a novel approach to treating various diseases.

Ubiquitin-Pathway Modulators

Nurix's ubiquitin-pathway modulators are small molecules that target specific components of the ubiquitin-proteasome pathway, which regulates protein degradation and cellular regulation.

8. Nurix Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Nurix Therapeutics, Inc. operates in a highly competitive industry, but the threat of substitutes is mitigated by the company's focus on novel and innovative therapies.

Bargaining Power Of Customers

Nurix Therapeutics, Inc. has a diverse customer base, and no single customer has significant bargaining power over the company.

Bargaining Power Of Suppliers

Nurix Therapeutics, Inc. relies on a few key suppliers for raw materials and equipment, but the company has developed relationships with multiple suppliers to mitigate risk.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market with innovative products and services.

Intensity Of Rivalry

Nurix Therapeutics, Inc. operates in a highly competitive industry, and the company faces intense rivalry from established players and new entrants.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 13.25%
Debt Cost 3.95%
Equity Weight 86.75%
Equity Cost 14.44%
WACC 13.05%
Leverage 15.27%

11. Quality Control: Nurix Therapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Xoma

A-Score: 4.3/10

Value: 6.4

Growth: 2.0

Quality: 4.6

Yield: 0.0

Momentum: 9.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
CASI Pharmaceuticals

A-Score: 3.5/10

Value: 9.6

Growth: 5.3

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Altimmune

A-Score: 3.3/10

Value: 6.8

Growth: 3.4

Quality: 3.2

Yield: 0.0

Momentum: 5.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Nutriband

A-Score: 3.0/10

Value: 6.2

Growth: 3.6

Quality: 3.8

Yield: 0.0

Momentum: 3.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Capricor Therapeutics

A-Score: 2.7/10

Value: 6.6

Growth: 4.3

Quality: 4.9

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Nurix Therapeutics

A-Score: 2.6/10

Value: 6.6

Growth: 1.9

Quality: 4.8

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

21.45$

Current Price

21.45$

Potential

-0.00%

Expected Cash-Flows